47 completed, 9 terminated, 5 withdrawn, 3 active not recruiting. 39 Phase 2, 14 Phase 1, 10 Phase 3, 8 Phase 4.
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET [177Lu]Lu-DOTA-TATE, Octreotide LAR - Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 240 | 2025-05-30 | 2026-09-11 |
| Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Signifor - Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | Phase 2 | Recruiting | University Hospital Heidelberg | 28 | 2024-12-19 | 2025-01-13 |
| A Study of Pasireotide in People With Prolactinoma Pasireotide, SF-36 and HADS - Prolactin-Producing Pituitary Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 10 | 2024-02-27 | 2026-03-04 |
| Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia Pasireotide Diaspartate - Post-Bariatric Hypoglycemia | Phase 2 | Active not recruiting | RECORDATI GROUP | 93 | 2024-01-04 | 2026-09-17 |
| Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis Pasireotide 0.9 MG/ML, Saline water - Peritoneal Carcinomatosis | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2020-09-03 | 2024-02-08 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | Advanced Accelerator Applications | 226 | 2020-01-08 | 2026-01-21 |
| A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 HTL0030310, Pasireotide, Placebo - Healthy | Phase 1 | Completed | Nxera Pharma UK Limited | 42 | 2019-01-23 | 2025-02-19 |
| Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Pasireotide 0.3 MG/ML, Meal tolerance test (MTT) - Hypoglycemia, Reactive | Phase 4 | Unknown | Zealand University Hospital | 5 | 2018-06-01 | 2018-07-05 |
| Pasireotide in Hyperinsulinemic Hypoglycemia Pasireotide 0.6Mg Solution for Injection, Saline Solution - Congenital Hyperinsulinism, Insulinoma | Phase 2 | Withdrawn | Montefiore Medical Center | 2017-04-01 | 2021-05-14 | |
| Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia Pasireotide - Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia | Phase 1 | Completed | University of Colorado, Denver | 1 | 2017-03-22 | 2021-09-29 |
| Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Pasireotide, Placebo - Enterostomy | Phase 2 | Completed | Hospices Civils de Lyon | 57 | 2016-12-13 | 2025-12-19 |
| Safety and Efficacy Study of SOM230 s.c. in Cluster Headache SOM230, Placebo - Cluster Headache - Episodic and Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 28 | 2016-10-31 | 2021-01-05 |
| HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications Hydrocortisone, Pasireotide - Pancreatic Fistula, Pancreatic Neoplasms | Phase 4 | Active not recruiting | Helsinki University Central Hospital | 126 | 2016-05-01 | 2020-08-24 |
| Pasireotide Treatment for Neuroendocrine Tumor Pasireotide, Diazoxide - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2016-04-01 | 2022-03-04 | |
| SOM230 Ectopic ACTH-producing Tumors Pasireotide - Ectopic ACTH Syndrome | Phase 2 | Withdrawn | Cedars-Sinai Medical Center | 2015-12-01 | 2018-01-26 | |
| Treatment of Hypoglycemia Following Gastric Bypass Surgery Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity | Phase 4 | Completed | Zealand University Hospital | 11 | 2015-10-01 | 2018-03-07 |
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Pasireotide in Prevention of GI Toxicity Pasireotide - Hematological Malignancies | Phase 2 | Completed | Anthony Sung, MD | 37 | 2015-01-21 | 2021-11-17 |
| Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections Pasireotide 0.9 MG/ML - Surgical Complications | Completed | Helsinki University Central Hospital | 258 | 2014-07-01 | 2020-02-24 |
Showing 20 of 71. Sign in to see all of them.
Acromegaly (10) · Pituitary ACTH Hypersecretion (8) · Pituitary Neoplasms (7) · Neuroendocrine Tumors (6) · Carcinoid Tumor (5) · Hypoglycemia (5) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Congenital Hyperinsulinism (3) · Dumping Syndrome (3) · Gastro-enteropancreatic neuroendocrine tumor (3) · Hyperinsulinism (3) · ACTH Syndrome, Ectopic (2) · Adrenocortical Hyperfunction (2) · Carcinoma, Hepatocellular (2)
Novartis Pharmaceuticals (24) · Memorial Sloan Kettering Cancer Center (3) · RECORDATI GROUP (3) · Emory University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Helsinki University Central Hospital (2) · Montefiore Medical Center (2) · NYU Langone Health (2) · Zealand University Hospital (2) · Advanced Accelerator Applications (1) · Alliance Pour La Recherche en Cancerologie (1) · Anthony Sung, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1)
United States (46) · Germany (24) · France (21) · Italy (17) · Belgium (15) · United Kingdom (14) · Spain (12) · Brazil (11) · Canada (11) · Netherlands (11) · Argentina (9) · Poland (8) · Turkey (Türkiye) (8) · Israel (7) · China (6)
David L Kleinberg, MD (2) · Annamaria Colao (1) · Anthony Sung, MD (1) · Bassel El-Rayes, MD (1) · Berthold Schalke, Prof. Dr. (1) · Caroline C Gormsen, M.D. (1) · Deborah Axelrod, MD (1) · Eliza Geer, MD (1) · Erika Brutsaert, M.D., M.P.H. (1)
PMID 27405306, PMID 20410233, PMID 22282526, PMID 22397653, PMID 22736724, PMID 23529827, PMID 23733372, PMID 23746264, PMID 23943009, PMID 24287689, PMID 24800725, PMID 24849084, PMID 25103549, PMID 25260838, PMID 25376618, PMID 25385439, PMID 25537481, PMID 26126727, PMID 26437217, PMID 27039081, PMID 27280398, PMID 28289402, PMID 28721067, PMID 29032078, PMID 29074099, PMID 29155991, PMID 29313180, PMID 29451701, PMID 29572709, PMID 31440946, PMID 31465533, PMID 31804965, PMID 31875276, PMID 31907828, PMID 32022887, PMID 32117045, PMID 32217809, PMID 32385851, PMID 33973550, PMID 34275099, PMID 35427770, PMID 37876540, PMID 38851203, PMID 39570708, PMID 40473457, PMID 40934647, PMID 42604001
2004 (2), 2008 (2), 2009 (2), 2014 (2), 2005 (1), 2018 (1), 2019 (1), 2023 (1)